Ascendis Pharma AS (ASND NASDAQ) stock market data APIs
$270.8306
-2.16(-0.8%)
as of September 3, 2026
Try our APIs with
free plan!
Ascendis Pharma AS Financial Data Overview
Price chart is built with
Anychart
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Prev. Close
270.8306
Open
268.6675
High
272.2145
Low
267.7282
52 wk Range
186.054-282.15
Market Cap
17 534 M
P/E Ratio
20.0834
Shares Outstanding
65 593 K
Revenue
1 047 M
EPS
3.29
Beta
0.485
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Ascendis Pharma AS (top by weight)
Ticker
100-day Price Change
Weight
W311.XETRA
HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF - Accumulating
0.81
(12.3%)
9.06
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Ascendis Pharma AS data using free add-ons & libraries
Get Ascendis Pharma AS Fundamental Data
Ascendis Pharma AS Fundamental data includes:
- Net Revenue: 1 047 M
- EBITDA: 263 M
- Earnings Per Share: 13
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-13
- EPS/Forecast: 0.78
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ascendis Pharma AS News
New
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
For BioMarin Pharmaceutical BMRN, the FDA approval of Ascendis Pharma's ASND Yuviwel in February had created a problem — a new entrant targeting the same achondroplasia market as Voxzogo, its key r...
Eyconis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Eyconis Inc. REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Eyconis, Inc., a clinical-stage biotechnology company advancing next-generation, long-acting ophthalmic therapeutics, today annou...
European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading
European equities traded in the US as American depositary receipts opened the week slightly lower la PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes
On Sunday, BioMarin Pharmaceutical Inc.(NASDAQ:BMRN) reached a binding settlement with Ascendis Pharma A/S(NASDAQ:ASND)to resolve all global patent disputes regarding the medication Yuviwel. Ascendis...
Get Ascendis Pharma AS fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
